![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Departments of Pediatrics (S.B.K., M.T.P., E.T.C., D.G.M., R.N.H.) and Pharmacology/Toxicology (D.G.M., R.N.H.), Medical College of Wisconsin, Milwaukee, Wisconsin
The flavin-containing monooxygenases (FMOs) are important for xenobiotic metabolism. FMO3, the predominant FMO enzyme in human adult liver, exhibits significant interindividual variation that is poorly understood. This study was designed to identify common FMO3 genetic variants and determine their potential for contributing to interindividual differences in FMO3 expression. FMO3 single nucleotide polymorphism (SNP) discovery was accomplished by resequencing DNA samples from the Coriell Polymorphism Discovery Resource. Population-specific SNP frequencies were determined by multiplexed, single-base extension using DNA from 201 Hispanic American (Mexican descent), 201 African American, and 200 White (northern European descent) subjects. Haplotypes were inferred and population frequencies estimated using PHASE version 2.1. Multiple site-directed mutagenesis was used to introduce inferred upstream haplotypes into an FMO3/luciferase construct for functional analysis in HepG2 cells. Sequence analysis revealed seven FMO3 upstream SNPs, 11 exon SNPs, and 22 intron SNPs. Five of the latter fell within consensus splice sites. A g.72G>T variant (E24D) is predicted to impact the structure of the Rossmann fold involved in FAD binding, whereas a g.11177C>A variant (N61K) is predicted to disrupt the secondary structure of a conserved membrane interaction domain. Seven common (>1%) promoter region haplotypes were inferred in one or more of the study populations that differed in estimated frequency among the groups. Haplotype 2 resulted in an 8-fold increase in promoter activity, whereas haplotypes 8 and 15 exhibited a near complete loss of activity. In conclusion, FMO3 promoter haplotype variants modulate gene function and probably contribute to interindividual differences in FMO3 expression.
Address correspondence to: Ronald N. Hines, Department of Pediatrics, Medical College of Wisconsin, 8701 Watertown Plank Rd., Milwaukee, WI 53226. E-mail: rhines{at}mail.mcw.edu
This article has been cited by other articles:
|
|
 |
|
  A. A. Francois, C. R. Nishida, P. R. O. de Montellano, I. R. Phillips, and E. A. Shephard Human Flavin-Containing Monooxygenase 2.1 Catalyzes Oxygenation of the Antitubercular Drugs Thiacetazone and Ethionamide Drug Metab. Dispos., January 1, 2009; 37(1): 178 - 186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Stevens, S. A. Marsh, M. J. Zaya, K. J. Regina, K. Divakaran, M. Le, and R. N. Hines Developmental Changes in Human Liver CYP2D6 Expression Drug Metab. Dispos., August 1, 2008; 36(8): 1587 - 1593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Koukouritaki, M. T. Poch, M. C. Henderson, L. K. Siddens, S. K. Krueger, J. E. VanDyke, D. E. Williams, N. M. Pajewski, T. Wang, and R. N. Hines Identification and Functional Analysis of Common Human Flavin-Containing Monooxygenase 3 Genetic Variants J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 266 - 273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Borbas, J. Zhang, M. A. Cerny, I. Liko, and J. R. Cashman Investigation of Structure and Function of a Catalytically Efficient Variant of the Human Flavin-Containing Monooxygenase Form 3 Drug Metab. Dispos., December 1, 2006; 34(12): 1995 - 2002. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Zhang and J. R. Cashman QUANTITATIVE ANALYSIS OF FMO GENE mRNA LEVELS IN HUMAN TISSUES Drug Metab. Dispos., January 1, 2006; 34(1): 19 - 26. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
